Results 151 to 160 of about 3,657 (192)
Some of the next articles are maybe not open access.
Delamanid in the treatment of multidrug-resistant tuberculosis
The International Journal of Tuberculosis and Lung Disease, 2016Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development. Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has ...
R, Gupta +4 more
openaire +2 more sources
Delamanid for Extensively Drug-Resistant Tuberculosis
New England Journal of Medicine, 2015Therapeutic options for extensively drug-resistant tuberculosis infection are limited. In this post-hoc analysis, a new drug, delamanid, shows some activity in the treatment of XDR-TB.
Rajesh, Gupta +5 more
openaire +2 more sources
Delamanid for the treatment of pulmonary multidrug resistant tuberculosis
Drugs of Today, 2015Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis.
R, Thakare +3 more
openaire +2 more sources